SOON-SHIONG PATRICK 4

What Happened

• Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific & Medical Officer of ImmunityBio (IBRX), acquired 4,606,596 shares on March 31, 2026 by converting a derivative security (a promissory note). The Form 4 reports the conversion at $5.43 per share, for a total value of $24,999,996 (footnote clarifies a conversion price of $5.427/share and that Nant Capital elected to convert $25,000,000 of principal into shares).

Key Details

• Transaction date: March 31, 2026; Conversion price reported: $5.43/share (footnote: $5.427/share).
• Shares acquired: 4,606,596; Reported value: $24,999,996.
• Shares owned after transaction: Not specified in the provided filing excerpt — see the full Form 4 for post-transaction beneficial ownership totals.
• Notable footnotes: Shares were issued to Nant Capital, LLC (an investment vehicle related to the reporting person). Multiple affiliated entities (e.g., Cambridge Equities, NantBio, CalCap, NantWorks and related vehicles) are referenced in the filing and may affect beneficial ownership attribution.
• Reporting status: Filed April 2, 2026 for a March 31, 2026 conversion (no late-filing flag shown in the excerpt provided).

Context

• This was a conversion of debt into equity (not an open-market purchase or option exercise sold for cash). The conversion right arose under a promissory note that allowed Nant Capital to convert principal into common stock between Dec 10, 2024 and Dec 31, 2027; the filing reports exercise of that conversion right.
• As a ~10% owner and company founder/executive, Soon-Shiong’s transactions are significant for ownership structure but do not necessarily signal routine executive buying/selling motives. For full ownership impact, review the complete Form 4 for aggregated holdings across the affiliated entities listed in the footnotes.